Back From Vancouver With Portfolio Updates
I had a wonderful time meeting many of you in Vancouver last week. I enjoyed spending time with attendees from past years, as well as making some new friends. Now that I'm back, I'd like to update you on some of our biotech recommendations. Following on U.S. regulatory approval earlier this year, Vertex (NASDAQ: VRTX) just received approval in Europe for Kalydeco. By correcting for defective proteins regulating the transport of ions across cellular membranes, Kalydeco is the first-ever available cystic fibrosis therapy attacking the roots of the disease.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.